Cellular and Molecular Life Sciences CMLS

, Volume 63, Issue 17, pp 2067–2077

A VEGF-A splice variant defective for heparan sulfate and neuropilin-1 binding shows attenuated signaling through VEGFR-2

  • S. Cébe Suarez
  • M. Pieren
  • L. Cariolato
  • S. Arn
  • U. Hoffmann
  • A. Bogucki
  • C. Manlius
  • J. Wood
  • K. Ballmer-Hofer
Research Article

DOI: 10.1007/s00018-006-6254-9

Cite this article as:
Cébe Suarez, S., Pieren, M., Cariolato, L. et al. Cell. Mol. Life Sci. (2006) 63: 2067. doi:10.1007/s00018-006-6254-9

Abstract.

The development of functional blood and lymphatic vessels requires spatio-temporal coordination of the production and release of growth factors such as vascular endothelial growth factors (VEGFs). VEGF family proteins are produced in multiple isoforms with distinct biological properties and bind to three types of VEGF receptors. A VEGF-A splice variant, VEGF-A165b, has recently been isolated from kidney epithelial cells. This variant is identical to VEGF-A165 except for the last six amino acids encoded by an alternative exon. VEGF-A165b and VEGF-A165 bind VEGF receptors 1 and 2 with similar affinity. VEGF-A165b elicits drastically reduced activity in angiogenesis assays and even counteracts signaling by VEGF-A165. VEGF-A165b weakly binds to heparan sulfate and does not interact with neuropilin-1, a coreceptor for VEGF receptor 2. To determine the molecular basis for altered signaling by VEGF-A165b we measured VEGF receptor 2 and ERK kinase activity in endothelial cells in culture. VEGF-A165 induced strong and sustained activation of VEGF receptor 2 and ERK-1 and −2, while activation by VEGF-A165b was only weak and transient. Taken together these data show that VEGF-A165b has attenuated signaling potential through VEGF receptor 2 defining this new member of the VEGF family as a partial receptor agonist.

Keywords.

VEGFsplicingheparinneuropilintyrosine kinaseangiogenesissignal transductionMAP kinase

Copyright information

© Birkhäuser Verlag, Basel 2006

Authors and Affiliations

  • S. Cébe Suarez
    • 1
  • M. Pieren
    • 1
  • L. Cariolato
    • 1
  • S. Arn
    • 1
  • U. Hoffmann
    • 1
  • A. Bogucki
    • 2
  • C. Manlius
    • 3
  • J. Wood
    • 3
  • K. Ballmer-Hofer
    • 1
  1. 1.Laboratory of Biomolecular Research, Molecular Cell BiologyPaul Scherrer InstitutVilligenSwitzerland
  2. 2.Friedrich Miescher InstituteBaselSwitzerland
  3. 3.Novartis Pharma LtdBaselSwitzerland